azd8601
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 16, 2016 (NCT02935712)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor ASupplementation
VEGFA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd8601
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03370887 | Phase 2 | Feb 5, 2018 | AstraZeneca, University of Turku |
| NCT02935712 | Phase 1 | Dec 16, 2016 | AstraZeneca, Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
| University of Turku | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1